Showing results (201-210 of 1,329) with videos related to
Sort By:
Pageof 133
Cell Cycle (Georgetown, Tex.)|February 22, 2007
The neuroendocrine impact of chronic stress on cancerPremal H Thaker, Susan K Lutgendorf, Anil K SoodPlant Physiology|November 1, 1984
Metabolism of Monoterpenes : Early Steps in the Metabolism of d-Neomenthyl-beta-d-Glucoside in Peppermint (Mentha piperita) RhizomesR Croteau, V K Sood, B Renstrøm, et al.Expert Opinion on Biological Therapy|November 30, 2012
Contemporary use of bevacizumab in ovarian cancerTakahito M Miyake, Anil K Sood, Robert L ColemanCancer Research|February 25, 2010
The dicey role of Dicer: implications for RNAi therapyWilliam M Merritt, Menashe Bar-Eli, Anil K SoodExpert Opinion on Biological Therapy|January 23, 2010
Farletuzumab in epithelial ovarian carcinomaWhitney A Spannuth, Anil K Sood, Robert L ColemanAmerican Journal of Obstetrics and Gynecology|April 4, 2007
Concomitant BRCA1 and BRCA2 gene mutations in an Ashkenazi Jewish woman with primary breast and ovarian cancerWhitney A Spannuth, Premal H Thaker, Anil K SoodJournal of Pharmaceutical Sciences|March 1, 1985
Quantitative liquid chromatographic determination of bromadoline and its N-demethylated metabolites in blood, plasma, serum, and urine samplesG W Peng, V K Sood, U M RykertIndian Journal of Pathology & Microbiology|January 1, 1994
Erythrocyte T-activation: clinical importance & recognition by a simple routine techniqueS Sethi, N Dhingra, N Madan, et al.Nature Communications|September 4, 2014
Flocking at a distance in active granular matterNitin Kumar, Harsh Soni, Sriram Ramaswamy, et al.Expert Opinion on Therapeutic Targets|November 23, 2005
EphA2 as a target for ovarian cancer therapyCharles N Landen, Michael S Kinch, Anil K SoodPageof 133